Resistant hypertension (RHTN) continues to significantly contribute to the overall population’s cardiovascular morbidity and mortality. Depending on the cohort assessed, the prevalence of RHTN is reported to range between 8 and 18 %. Hypertension treatment consists of life style intervention, pharmacological approaches and use of novel devices—renal nerve denervation, baroreflex activation therapy, carotid body ablation, central iliac arteriovenous anastomosis, deep brain stimulation, median nerve stimulation, and vagal nerve stimulation. We aim to create an innovative medical device that will help diagnose hypertension, evaluate outpatient treatment efficacy, perform remote ischemic preconditioning, will exhibit cardioprotective properties and improve antihypertensive drug efficacy.
Project funding:
KTU Research and Innovation Fund
Period of project implementation: 2020-04-06 - 2020-12-31
Project partners: Lithuanian University of Health Sciences
